1. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
- Author
-
J. Tabernero, L. Velez, T.L. Trevino, A. Grothey, R. Yaeger, E. Van Cutsem, H. Wasan, J. Desai, F. Ciardiello, T. Yoshino, A. Gollerkeri, K. Maharry, J. Christy-Bittel, S. Kopetz, Tabernero, J., Velez, L., Trevino, T. L., Grothey, A., Yaeger, R., Van Cutsem, E., Wasan, H., Desai, J., Ciardiello, F., Yoshino, T., Gollerkeri, A., Maharry, K., Christy-Bittel, J., Kopetz, S., Institut Català de la Salut, [Tabernero J, Velez L] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVIC-UCC, IOB-Quiron, Barcelona, Spain. [Trevino TL] Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. [Grothey A] West Cancer Center and Research Institute, OneOncology, Germantown, USA. [Yaeger R] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA. [Van Cutsem E] Digestive Oncology Department, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Proto-Oncogene Proteins B-raf ,Cancer Research ,adverse event ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,encorafenib ,Review ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] ,Còlon - Càncer - Tractament ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES] ,Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Antineoplastic Combined Chemotherapy Protocols ,Recte - Càncer - Tractament ,cetuximab ,Other subheadings::Other subheadings::/adverse effects [Other subheadings] ,Humans ,neoplasms ,Sulfonamides ,Medicaments - Efectes secundaris ,metastatic colorectal cancer ,terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES] ,digestive system diseases ,adverse events ,CRC ,Oncology ,Mutation ,Carbamates ,Colorectal Neoplasms - Abstract
Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC). Patients with BRAF V600E mutations, which occur in ∼10%-15% of patients with mCRC, have a poorer prognosis compared with those with wild-type BRAF tumours. The combination of the BRAF inhibitor encorafenib with the epidermal growth factor receptor inhibitor cetuximab currently represents the only chemotherapy-free targeted therapy approved in the USA and Europe for previously treated patients with BRAF V600E-mutated mCRC. As a class, BRAF inhibitors are associated with dermatologic, gastrointestinal, and renal events, as well as pyrexia and secondary skin malignancies. Adverse event (AE) profiles of specific BRAF inhibitors vary, however, and are affected by the specific agents given in combination. In patients with mCRC, commonly reported AEs of cetuximab monotherapy include infusion reactions and dermatologic toxicities. Data from the phase III BEACON CRC study indicate that the combination of encorafenib with cetuximab has a distinct safety profile. Here we review the most frequently reported AEs that occurred with this combination in BEACON CRC and best practices for managing and mitigating AEs that require more than standard supportive care., Highlights • Encorafenib + cetuximab has a distinct safety profile in patients with BRAF V600E-mutated metastatic colorectal cancer. • Effective management strategies can mitigate the impact of AEs, prolonging treatment duration and benefits. • We provide guidance on managing gastrointestinal, skin, and renal AEs. • Specific guidance is given for the management of arthralgia, myalgia, fatigue, asthenia, headache, and pyrexia.
- Published
- 2021